← UNITED THERAPEUTICS Corp
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.6b | $1.7b | $1.6b | $1.4b | $1.5b | $1.7b | $1.9b | $2.3b | $2.9b | $3.2b | |
| Cost of Revenue | $72.7m | $105.7m | $198.7m | $117.6m | $108.1m | $122.5m | $151.6m | $257.5m | $309.7m | $384.4m | |
| Gross Profit (derived) | $1.5b | $1.6b | $1.4b | $1.3b | $1.4b | $1.6b | $1.8b | $2.1b | $2.6b | $2.8b | |
| Operating expenses: | |||||||||||
| Operating Income (Loss) | $1.1b | $814.9m | $805.4m | ($187.6m) | $593.6m | $555.9m | $979.7m | $1.2b | $1.4b | $1.5b | |
| Additional Financial Items | |||||||||||
| Amortization of Intangible Assets | $600k | $500k | $100k | $200k | $200k | $100k | $100k | $300k | $900k | $900k | |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount | — | — | — | — | — | $2.3m | $1.7m | $0 | $0 | — | |
| Goodwill, Impairment Loss | $0 | $0 | $0 | — | $0 | $0 | $0 | $0 | $0 | $0 | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | — | — | — | — | $1.7b | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $1.1b | $769.5m | $758.9m | ($165.0m) | $638.9m | $593.9m | $950.6m | $1.3b | $1.5b | $1.7b | |
| Net Income (Loss) Attributable to Parent | $713.7m | $417.9m | $589.2m | ($104.5m) | $514.8m | $475.8m | $727.3m | $984.8m | $1.2b | $1.3b | |
| Net Income (Loss) Available to Common Stockholders, Basic | $713.7m | $417.9m | $589.2m | ($104.5m) | $514.8m | $475.8m | $727.3m | $984.8m | $1.2b | $1.3b | |
| Earnings Per Share, Basic | $16.29 | $9.50 | $13.54 | ($2.39) | $11.65 | $10.60 | $15.98 | $21.04 | $26.44 | $30.13 | |
| Earnings Per Share, Diluted | $15.25 | $9.31 | $13.39 | ($2.39) | $11.54 | $10.06 | $15.00 | $19.81 | $24.64 | $27.86 | |
| Weighted Average Number of Shares Outstanding, Basic | 43.8m | 44.0m | 43.5m | 43.8m | 44.2m | 44.9m | 45.5m | 46.8m | 45.2m | 44.3m | |
| Weighted Average Number of Shares Outstanding, Diluted | 46.8m | 44.9m | 44.0m | 43.8m | 44.6m | 47.3m | 48.5m | 49.7m | 48.5m | 47.9m | |
| Research and Development Expense | $147.6m | $264.6m | $357.9m | $1.2b | $357.7m | $540.1m | $322.9m | $408.0m | $481.0m | $550.0m | |
| Selling, General and Administrative Expense | $316.8m | $330.1m | $265.8m | $336.2m | $423.9m | $467.0m | $482.1m | $477.1m | $709.7m | $755.8m | |
| Other Nonoperating Income (Expense) | $2.4m | $13.2m | ($7.7m) | $22.6m | $49.3m | $42.2m | ($40.2m) | ($14.0m) | $5.8m | $48.9m | |
| Interest Expense (non-operating) | — | — | — | — | — | — | — | — | $42.9m | $19.5m | |
| Business Combination, Acquisition Related Costs | — | — | $5.4m | — | — | — | — | — | — | — | |
| Costs and Expenses | $537.1m | $910.4m | $822.4m | $1.6b | $889.7m | $1.1b | $956.6m | $1.1b | $1.5b | $1.7b | |
| Current Income Tax Expense (Benefit) | $336.0m | $285.2m | $154.0m | $72.5m | $134.6m | $136.9m | $274.1m | $353.9m | $408.0m | $281.5m | |
| Interest Expense | $3.9m | $9.0m | $13.9m | $44.2m | $23.5m | $18.6m | $32.4m | $59.3m | $42.9m | $19.5m | |
| Operating Lease, Expense | — | — | — | — | $3.5m | $3.6m | $4.8m | — | — | — | |
| Income Tax Expense (Benefit) | $346.5m | $351.6m | $169.7m | ($60.5m) | $124.1m | $118.1m | $223.3m | $289.5m | $343.9m | $379.2m | |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement | — | — | — | — | — | $0 | — | $1.8m | $0 | $600k |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.